In both chronic viral infection and cancer, blocking TIM-3 ex vivo or in vivo increases the functionality of exhausted T cells and synergizes with PD-1 blockade to restore viral control (46, 52) or to inhibit tumor growth (48, 49). The gene discussed is HAVCR2; the disease is neoplasm.